UBS Group
LABU icon

UBS Group’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

UBS Group’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$407K Buy
2,450
+198
+9% +$32.5K ﹤0.01% 6225
2025
Q4 		$359K Buy
2,252
+952
+73% +$131K ﹤0.01% 6265
2025
Q3 		$122K Sell
1,300
-6,284
-83% -$444K ﹤0.01% 6988
2025
Q2 		$432K Sell
7,584
-28,015
-79% -$1.49M ﹤0.01% 6131
2025
Q1 		$2.17M Buy
35,599
+11,115
+45% +$947K ﹤0.01% 4633
2024
Q4 		$2.2M Buy
+24,484
New +$2.88M ﹤0.01% 4639
2024
Q3 		– Sell
-4,372
Closed -$496K – 9814
2024
Q2 		$496K Sell
4,372
-431
-9% -$46.1K ﹤0.01% 5009
2024
Q1 		$637K Buy
4,803
+1,925
+67% +$251K ﹤0.01% 5003
2023
Q4 		$351K Buy
+2,878
New +$220K ﹤0.01% 5382
2023
Q3 		– Sell
-418
Closed -$49.5K – 9735
2023
Q2 		$49.5K Sell
418
-2,936
-88% -$366K ﹤0.01% 6482
2023
Q1 		$329K Buy
3,354
+1,714
+105% +$232K ﹤0.01% 5005
2022
Q4 		$232K Sell
1,640
-453
-22% -$63.2K ﹤0.01% 5342
2022
Q3 		$293K Buy
2,093
+1,537
+276% +$282K ﹤0.01% 4790
2022
Q2 		$75K Sell
556
-116
-17% -$19.8K ﹤0.01% 5631
2022
Q1 		$211K Buy
672
+537
+398% +$202K ﹤0.01% 5311
2021
Q4 		$97K Sell
135
-100
-43% -$95.7K ﹤0.01% 6341
2021
Q3 		$260K Sell
235
-889
-79% -$1.09M ﹤0.01% 5129
2021
Q2 		$1.66M Buy
1,124
+879
+359% +$1.22M ﹤0.01% 3746
2021
Q1 		$386K Buy
245
+198
+421% +$464K ﹤0.01% 5059
2020
Q4 		$94K Sell
47
-125
-73% -$199K ﹤0.01% 5733
2020
Q3 		$184K Buy
172
+131
+320% +$150K ﹤0.01% 4838
2020
Q2 		$49K Buy
+41
New +$35.6K ﹤0.01% 5874
2020
Q1 		– Sell
-19
Closed -$22K – 8186
2019
Q4 		$22K Buy
19
+12
+171% +$10.8K ﹤0.01% 6817
2019
Q3 		$4K Sell
7
-43
-86% -$35.7K ﹤0.01% 7554
2019
Q2 		$51K Sell
50
-3
-6% -$2.9K ﹤0.01% 5911
2019
Q1 		$63K Buy
+53
New +$55.1K ﹤0.01% 5377
2018
Q4 		– Sell
-53
Closed -$99K – 8172
2018
Q3 		$99K Buy
53
+6
+13% +$11.8K ﹤0.01% 5610
2018
Q2 		$90K Buy
+47
New +$82.8K ﹤0.01% 5515
2017
Q3 		– Sell
-20
Closed -$26K – 7869
2017
Q2 		$26K Sell
20
-157
-89% -$158K ﹤0.01% 6110
2017
Q1 		$169K Buy
+177
New +$158K ﹤0.01% 4743
2016
Q4 		– Sell
-110
Closed -$107K – 7903
2016
Q3 		$107K Sell
110
-63
-36% -$52K ﹤0.01% 4950
2016
Q2 		$98K Buy
173
+166
+2,371% +$104K ﹤0.01% 5044
2016
Q1 		$4K Buy
7
+3
+75% +$1.9K ﹤0.01% 7092
2015
Q4 		$7K Sell
4
-4
-50% -$6.48K ﹤0.01% 7514
2015
Q3 		$11K Buy
+8
New +$24.4K ﹤0.01% 7205

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group's LABU Position: Q1 2026 in Review

UBS Group increased its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 8.8% in Q1 2026, buying an estimated $32.5K and bringing the position to 2,450 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #6225.

UBS Group first reported a position in LABU in Q3 2015 and has held it in 35 quarters since. The position peaked at $2.2M in Q4 2024. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • UBS Group held 2,450 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $407K as of Q1 2026.
  • UBS Group bought 198 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $32.5K.
  • Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6225 holding.
  • UBS Group first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2015 and has held it in 35 quarters since.
  • UBS Group's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $2.2M in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.